Skip to main content
Clinical Trials/NCT03303794
NCT03303794
Terminated
Phase 3

Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study

Montefiore Medical Center1 site in 1 country25 target enrollmentOctober 25, 2017

Overview

Phase
Phase 3
Intervention
0.25% bupivacaine
Conditions
Anesthesia
Sponsor
Montefiore Medical Center
Enrollment
25
Locations
1
Primary Endpoint
AM-PAC Score to Measure Patients Fitness for Discharge
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

Total knee and hip replacements are some of the most common orthopedic procedures that require aggressive postoperative pain management. This management helps us to improve clinical outcomes such as participation in early physical therapy, hospital discharge, and patient satisfaction. Based on the recent anatomical evidence and the investigator's knowledge of the complexity of the knee joint innervation the investigator proposes a new regional anesthesia technique that provides a complete sensory blockade and better analgesia while preserving the quadriceps strength and avoiding the potential for foot drop caused by inadvertent blockade of the common peroneal nerve.

Detailed Description

This is an assessor-blinded randomized controlled trial evaluating the efficacy of liposomal bupivacaine (Exparel) in patients undergoing Total Knee Arthroplasty. The primary outcome of this study is the proportion of patients "fit to discharge" on postoperative day one. Recently, liposomal bupivacaine (LB) (Exparel) was introduced into clinical practice, using a lipid-based depot (DepoFoam) technology for sustained release of bupivacaine. LB (Exparel) uses this technology to extend the delivery of bupivacaine, a local anesthetic that has been used in clinical practice for decades for peripheral nerve block, spinal, and epidural analgesia and anesthesia. This formulation prolongs the duration of analgesia of bupivacaine for up to 72 hours with a single injection. The study was designed to compare two of our current standard therapies: 1. Adductor Canal Block + Tissue Infiltration (lateral, medial and femoral compartment + posterior capsule tissue infiltration using 0.25% bupivacaine; and 2. Adductor Canal Block + Tissue Infiltration (lateral, medial and femoral compartment + posterior capsule tissue infiltration) using 1:1 mixture of 1.3% LB (Exparel) + 0.5% bupivacaine HCl mixture.

Registry
clinicaltrials.gov
Start Date
October 25, 2017
End Date
June 27, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Singh Nair

Investigator

Montefiore Medical Center

Eligibility Criteria

Inclusion Criteria

  • All patients undergoing unilateral total knee replacement due to OA or rheumatoid arthritis
  • Ages 40- 80 years old
  • American Society of Anesthesiologists class I-III

Exclusion Criteria

  • Refusal or absolute medical contraindication to peripheral nerve block
  • refusal or absolute medical contraindication to spinal anesthesia
  • conversion of spinal anesthesia to general anesthesia is obtained
  • inability to cooperate
  • allergy to any drug used in this study
  • daily intake of opioids (tramadol, morphine, oxycodone, methadone, fentanyl)
  • alcohol dependence or use of any illegal drugs within the last month
  • inability to perform the mobilization test and timed up and go (TUG) test pre-operatively

Arms & Interventions

Bupivicaine

0.25% bupivacaine in patients undergoing total knee arthroplasty

Intervention: 0.25% bupivacaine

Bupivicaine + Exparel

0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty

Intervention: Exparel

Bupivicaine + Exparel

0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty

Intervention: 0.25% bupivacaine

Outcomes

Primary Outcomes

AM-PAC Score to Measure Patients Fitness for Discharge

Time Frame: Post-Operation Day 1

AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge.

Secondary Outcomes

  • Opioid Consumption During the First 48 Hours After TKA Surgery(During the first 48 hours after surgery)
  • Pain Scores During 48 Hrs Postoperatively(48 hours postoperatively)

Study Sites (1)

Loading locations...

Similar Trials